Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-23
2007-10-23
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S251000, C544S252000
Reexamination Certificate
active
11486193
ABSTRACT:
The present invention discloses compounds corresponding to formula I:wherein A, Z, Z1, Y, R1and R2are as defined in the specification, as well as pharmaceutical formulations, methods of making and uses thereof.
REFERENCES:
patent: 4522947 (1985-06-01), Musser et al.
patent: 4650737 (1987-03-01), Wiedemann
patent: 4656281 (1987-04-01), Musser et al.
patent: 4831040 (1989-05-01), Decktor et al.
patent: 0542497 (1993-05-01), None
patent: 11-292878 (1998-04-01), None
patent: WO 02/064594 (2002-08-01), None
Graninger et al. Curr. Opin. Rheumatol. 13(3): 209-213.
Brunet et al., Esaays Biochem. 32 : 1-16, 1997.
Herlaar et al. Mol. Med. Today 5(10) 439-447,1999.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Ahn, N.G., et al., “Multiple Components in an Epidermal Growth Factor-stimulated Protein Kinase Cascade,”The Journal of Biological Chemistry, 1991, 266 (7): 4220-4227.
Barancik, M., et al., “SB203580, a specific inhibitor of p38-MAPK pathway, is a new reveral agent of P-glycoprotein-mediated multidrug resistance,”Eur. Journal Pharma. Sciences2001, 14: 29-36.
Denkert, C., et al. “An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells,”Clinical&Experimental Metastasis2002, 19: 79-85.
Graninger, W.B., et al., “One-year inhibition of tumor necrosis factor-α: a major success or a larger puzzle?”Curr. Opin. in Rheumatol.2001, 13: 209-213.
Greenberg, A.K., et. al., “Selective p38 Activation in Human Non-Small Cell Lung Cancer,”Am. J. Respir. Cell Mol. Biol.2002, 26: 558-564.
Hashimoto, S., et al., “Selective Inhibitor of p38 Mitogen-Activated Protein Kinase Inhibits Lipopolysaccaride-Induced Interleukin-8 Expression in Human Pulmonary Vascular Endothelial Cells,”J. Pharmacol. And Experimental Therap.2000, 293 (2): 370-375.
Herlaar, E., et al., “P38 MAPK signaling cascades in inflammatory disease,”Molecular Medicine Today, 1999 (5): 439-447.
Hotamisligil, G.S., et. al., “Inflammation and metabolic disorders,”Nature2006, 444: 860-867.
Hull, M., et. al., “Pathways of Inflammatory Activation in Alzheimer's Disease: Potential Targets for Disease Modifying Drugs,”Current Medicinal Chemistry2002, 9: 83-88.
Iwata, Y., et. al., “p38 Mitogen-Activated Protein Kinase Contributes to Autoimmune Renal Injury in MRL-Fas1prMice,”J. Am. Nephrol.2003, 14: 57-67.
Lee, J.C., et al., “p38 Mitogen-Activated Protein Kinase Inhibitors Mechanisms and Therapeutic Potentials,”Pharmacol. Ther.1999, 82 (2-3): 389-397.
New, L., et. al., “The p38 MAP Kinase Pathway and Its Biological Function,”TCM1998, 8 (5): 220-228.
Pol, A., et. al., “A Simple Technique for High-Throughput Screening of Drugs that Modulate Normal and Psoriasis-Like Differentiation in Cultured Human Keratinocytes,”Skin Pharmacol. Appl. Skin Physiol.2002, 15: 252-261.
Puigerver, P., et al., “Cytokine Stimulation of Energy Expenditure through p38 MAP Kinase Activation of PPARγ Coactivator-1,”Molecular Cell2001, 8: 971-982.
Souza, R.F., et. al., “Acid Exposure Activated the Mitogen-Activated Protein Kinase Pathways in Barrett's Esophagus,”Gastroenterology2002, 122: 299-307.
Takahashi, S. et. al., “FR167653, a p38 Mitogen-Activated Protein Kinase Inhibitor, Prevents Helicobacter pylori-Induced Gastritis in Mongolian Gerbils,”J. Pharmacol. And Experimental Therap.2001, 296 (1): 48-56.
Thellung, S., et. al., “p38 MAP Kinase Mediates the Cell Death Induced by PrP106-126 in the SH-SY5Y Neuroblastoma Cells,”Neurobiology of Disease2002, 9: 69-81.
Thurmond, R.L., et al., “Kinetics of small molecule inhibitor binding to p38 kinase,”Eur. J. Biochem.,2001, 268: 5747-5754.
Underwood, D.C., et. al., “SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung,”Am. J. Physiol. Lung Cell Mol. Physiol.2000, 279: L895-L902.
Waetzig, G.H., et. al., “p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease,”J. Immunol.2002, 168: 5342-5351.
Goldstein David Michael
Hawley Ronald Charles
Lui Alfred Sui-Ting
Sjogren Eric Brian
Balasubramanian Venkataraman
Green Grant D.
Roche Palo Alto LLC
LandOfFree
Imidazo-substituted compounds as p38 kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo-substituted compounds as p38 kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo-substituted compounds as p38 kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858738